Compare MMT & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMT | PROF |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.4M | 243.2M |
| IPO Year | N/A | 2017 |
| Metric | MMT | PROF |
|---|---|---|
| Price | $4.54 | $6.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 97.4K | 66.8K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.58% | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ 0.30 | 0.19 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | ★ $15.07 | $36.37 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $4.37 | $3.92 |
| 52 Week High | $4.87 | $8.95 |
| Indicator | MMT | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 49.22 |
| Support Level | $4.38 | $6.54 |
| Resistance Level | $4.72 | $7.07 |
| Average True Range (ATR) | 0.05 | 0.31 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 75.00 | 25.27 |
MFS Multimarket Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests a majority of its net assets in fixed-income securities, corporate bonds of the U.S and foreign issuers, U.S Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S and foreign issuers, and debt instruments of issuers located in emerging market countries. The portfolio of investments comprises of different sector investments such as aerospace, automotive, chemicals, electronics, and others.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.